Please assess the completion status of the following clinical trial:

Trial Title: Honey & Nigella Sativa Trial Against COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result with SSC-2 score\> 5~* Patients admitted in Corona centers~Exclusion Criteria:~* Participants not giving consent.~* Pregnant and lactating females.~* History of allergy to any drug being administered in this study~* Severely terminally ill patients~* Patients on Nil Per Oral

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nigella Sativa & Honey Group (Type: EXPERIMENTAL): Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)~along with standard medical care
- Standard Medical Care (Type: PLACEBO_COMPARATOR): Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)

Based on this trial design, predict the completion outcome and termination type (if applicable).